CoChat
Sign Up
Cited by 136Rheumatoid Arthritis Research and TherapiesNatural Compounds in Disease TreatmentAutoimmune and Inflammatory Disorders Research

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Leflunomide: A Review of its Use in Active Rheumatoid Arthritis

Prakash, Amitabh, Jarvis, Blair·1999·Drugs
DOI 10.2165/00003495-199958060-00010
Open this paper in CoChat — free account

Abstract

Unlabelled A77 1726, the active metabolite of leflunomide, is an immunomodulator which inhibits cell proliferation in activated lymphocytes in patients with active rheumatoid arthritis. Because A77 1726 has a long half-life (approximately 2 weeks), treatment with oral leflunomide is initiated with a loading dose of 100mg once daily for 3 days and continued with 20mg once daily. Results of large randomised, double-blind, multicentre trials of up to 24 months' duration have shown that leflunomide is significantly superior to placebo and at least as effective as sulfasalazine in improving primary outcome measures, such as tender joint counts, swollen joint counts and physicians' and patients' global assessment, in adult patients with active rheumatoid arthritis. Whereas improvement in all primary outcome measures with leflunomide was similar to or significantly less than that with methotrexate after 12 months, the efficacy of both agents was similar after 24 months. The therapeutic effect of leflunomide appears earlier (at 4 weeks) than that of sulfasalazine or methotrexate, and reduction from baseline values in functional disability was significantly greater with leflunomide than with sulfasalazine, methotrexate or placebo at end-point. Leflunomide was at least as effective as sulfasalazine or methotrexate in delaying the rate of radiological progression of disease. The most common adverse events reported in patients receiving leflunomide in randomised double-blind, placebo-controlled trials were diarrhoea (27%), respiratory infections (21%), nausea (13%), headache (13%), rash (12%), increased serum hepatic aminotransferases (10%), dyspepsia (10%) and alopecia (9%). Leflunomide was as well tolerated as sulfasalazine or methotrexate in clinical trials. Monitoring of serum hepatic enzyme levels is recommended in patients receiving leflunomide. The drug is not recommended in female patients who are or may become pregnant. Drug treatment should be discontinued, and hastened drug elimination procedure should be considered, in male patients wishing to father a child. 16 potential cases of pancytopenia and 9 cases of serious skin reactions have been associated with the use of leflunomide in 76,000 patients to date. Conclusions Leflunomide is a disease-modifying antirheumatic drug which reduces the signs and symptoms of inflammatory arthritis and delays the radiological progression of disease in adult patients with active rheumatoid arthritis. The drug appears to be as effective and as well tolerated as sulfasalazine or methotrexate, and represents a suitable alternative to these agents in adult patients with active rheumatoid arthritis. Benefits with leflunomide are evident within 4 weeks and efficacy is maintained for durations of up to 24 months.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-199958060-00010

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 67 references

Cited by

Sorted by citations

Items 101–136 of 136

Related

See all

Metadata

Authors
Prakash, A., & Jarvis, B.
Corresponding author
Prakash, Amitabh
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
1999
Volume
58
Issue
6
Pages
1137-1164
ISSN
0012-6667 (ISSN-L)
DOI
10.2165/00003495-199958060-00010
OpenAlex
W2020790398
Cited by
135
References
67
Citations by year
2026: 5 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 1 · 2014: 4 · 2013: 5 · 2012: 6
FWCI
2.49
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords
leflunomide, rheumatoid arthritis, immunomodulation, sulfasalazine, methotrexate, disease-modifying antirheumatic drugs, drug safety, adverse events, hepatotoxicity, drug interactions, pregnancy contraindication, pancytopenia, skin reactions, radiographic progression, functional disability
MeSH terms
Leflunomide, Adult, Animals, Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Rheumatoid, Female, Humans, Isoxazoles, Male, Pregnancy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review